Novo Nordisk shares jump 5% on promising weight loss trial results; Eli Lilly dips

Novo Nordisk shares climbed 5% on Thursday morning, according to LSEG data, hitting a fresh record highs after the Danish pharmaceutical giant reported positive early trial data for a new experimental weight loss drug.The company told an investor meeting that the Phase I trial of its highly-anticipated obesity drug amycretin showed a 13.1% weight loss in participants after 12 weeks, according to Reuters. This reading eclipses the 6% loss recorded after a 12-week trial for the company's wildly popular obesit ...